Blair William & Co. IL Buys Shares of 27,230 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Blair William & Co. IL purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 27,230 shares of the company's stock, valued at approximately $1,508,000. Blair William & Co. IL owned 0.07% of Tarsus Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $25,000. Bank of New York Mellon Corp boosted its position in Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after purchasing an additional 498 shares during the period. Swiss National Bank boosted its position in Tarsus Pharmaceuticals by 1.2% during the fourth quarter. Swiss National Bank now owns 52,333 shares of the company's stock worth $2,898,000 after purchasing an additional 600 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of Tarsus Pharmaceuticals by 10.8% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,106 shares of the company's stock valued at $449,000 after purchasing an additional 789 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $53,000. Institutional investors and hedge funds own 90.01% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TARS. Guggenheim reiterated a "buy" rating and issued a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday, February 24th. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. HC Wainwright reissued a "buy" rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday, February 26th. Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Tarsus Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $63.67.

Remove Ads

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock traded up $0.47 during trading on Monday, hitting $47.49. The company had a trading volume of 907,593 shares, compared to its average volume of 679,282. The firm has a market capitalization of $1.82 billion, a P/E ratio of -12.46 and a beta of 0.94. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock's 50-day moving average price is $49.10 and its 200 day moving average price is $46.91.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, beating analysts' consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The firm had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Equities analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current fiscal year.

Insider Buying and Selling

In related news, General Counsel Bryan Wahl sold 3,084 shares of the company's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the sale, the general counsel now directly owns 51,712 shares in the company, valued at $2,591,288.32. This represents a 5.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bobak R. Azamian sold 8,534 shares of the firm's stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $427,638.74. Following the completion of the sale, the chief executive officer now directly owns 53,635 shares in the company, valued at $2,687,649.85. This trade represents a 13.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 32,542 shares of company stock valued at $1,581,173 over the last quarter. 8.25% of the stock is owned by company insiders.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.